Refine by MP, party, committee, province, or result type.
Health committee I'll invite Dr. Turner to respond with regard to the definition of post-market surveillance.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee Yes.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee Maybe I'll tell you how I look at it in terms of post-market surveillance. Basically, when a drug or health product is out on the market, we use a variety of means to collect information on that drug's use out in the market. Through MedEffect, through our Canadian adverse drug
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee We have a variety of partnerships in this country, with health care professionals; with provincial and territorial governments; with our partners such as the Canadian Institute for Health Information and the health technology body CADAS; and with international regulatory agencies
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee I will begin my answer in French, but with your permission—
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee All right. It is because I would like to give you an accurate answer. We are presently looking at our resource base, further to the AG's report and further to the investments that have been made in the past. We're considering what resources we need to carry out our regulatory r
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee I'll invite my colleague Mr. Lee to respond to that.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee No, I think we're fine. We'll just respond to the questions. Thank you.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee I would like to emphasize, Dr. Bennett, that you're absolutely right that we are increasing our efforts, making concerted efforts to get communications out to the public using a variety of sources. We have put into place mechanisms such as the MedEffect website that I talked abou
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee Thank you, Madam Chair. I'll start with the introductions. We have Diana Dowthwaite, who's our director general of the health products and food branch inspectorate; Dr. Chris Turner, who's the director general of marketed health products; Mr. David Lee, who is the director of th
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee Thank you very much, Madam Chair. It's a pleasure to be here today before this committee to provide an overview of Canada's post-market activities for pharmaceuticals. In my opening remarks I will provide an overview of the main components of our program, the measures the depart
January 31st, 2008Committee meeting
Meena Ballantyne